Glossary

Loss of coordination. It describes a symptom — movements that are imprecise or unsteady — not a single disease. Many different conditions cause ataxia.

It is not weakness. Muscles can be strong and still be poorly coordinated.

Shrinkage of a tissue. On a brain scan in SCA, atrophy of the cerebellum means that part of the brain has lost volume.

The stalk connecting the brain to the spinal cord. It handles swallowing, speech mechanics, eye movements and automatic functions like breathing.

The part of the brain at the back and base of the skull that fine-tunes movement. It does not decide to move; it makes the movement smooth, accurate and well-timed.

Speech that is hard to understand because the muscles used for speaking are not being coordinated precisely. The words and the thinking behind them are intact.

It is not a problem with language or with intelligence. Assuming otherwise is one of the most common and most hurtful mistakes people make.

Difficulty swallowing. It matters medically because food or liquid going into the airway can cause chest infections.

A condition in which nerve cells are progressively lost over time. It tells you the direction of travel, not the speed — which varies enormously between conditions and between people.

Involuntary rhythmic eye movements. It can make it harder to hold a steady gaze or to read comfortably.

A large, elaborately branched neuron in the cerebellum. These cells are central to how the cerebellum calibrates movement, and they are among the cells affected in SCA.

The tendency in some repeat-expansion conditions for the repeat to grow longer as it passes down a generation, associated on average with earlier onset in the child than the parent.

It is a statistical pattern across many families, not a prediction about any particular person.

An inheritance pattern where one altered copy of a gene is enough to cause the condition. Each child of an affected parent has, on average, a one-in-two chance of inheriting it.

The one-in-two chance applies independently to each pregnancy. It does not mean that in a family of four, two will be affected.

The specific genetic finding — which gene, and what change in it. In SCA this is what the number after the name refers to, as in SCA3.

How reliably a genetic change actually produces the condition. Some changes cause it in nearly everyone who carries them; others do not.

Genetic testing in someone who has no symptoms but has an affected relative. It answers whether they carry the change; it does not say when or how severely symptoms would begin. Genetic counselling before testing exists because the decision is genuinely difficult and the result cannot be undone.

A short sequence of DNA letters that is repeated more times than usual. Everyone has some repeats; in these conditions the run is abnormally long, and the length is what causes trouble.

A modified, shortened version of SARA focused on functional items, used as the main outcome measure in some SCA trials.

A clinic where several specialists see a person in a coordinated way rather than in separate appointments across months.

Research that follows people with a condition over time without giving them a treatment, to document how it usually progresses. It is what makes it possible to recognise later whether a treatment has changed anything.

A scored clinical examination used to measure how much ataxia someone has, covering things like walking, standing, speech and limb coordination. A higher score means more impairment.

Care aimed at function, comfort and safety rather than at the underlying disease process — physiotherapy, speech and language therapy, occupational therapy, equipment, and treatment of specific symptoms.

Not a lesser or last-resort option. In a condition with no disease-modifying drug, it is the main thing that changes how someone lives.

The specific thing a trial measures to decide whether the treatment worked, chosen and written down before the trial starts.

A route by which someone with a serious condition may be given an unapproved treatment outside a trial. Access is limited, controlled by the company and regulator, and never guaranteed.

A study design where treated participants are compared against data from people outside the study, such as a natural history cohort, rather than a group randomised at the same time. Sometimes the only practical option in very rare diseases, and harder to interpret because the two groups may differ in ways nobody accounted for.

A study where everyone knows who is receiving the treatment. Useful for tracking safety over long periods, weaker for establishing whether something works.

The stages of human testing. Phase 1 asks mainly about safety and dosing in a small group, phase 2 looks for early signs of effect, and phase 3 tests the treatment in a larger group to establish whether the effect is real.

A trial where the comparison group receives an inactive version, so the effect of the drug can be separated from the effect of being in a study and expecting to improve.

A study where participants are assigned by chance to receive the treatment or a comparison, so that the two groups are alike apart from the treatment. Randomisation is what allows a difference in outcome to be attributed to the drug.

Evidence drawn from data generated in ordinary clinical care rather than in a controlled trial — registries, medical records, cohort studies.

The FDA’s notice that it will not approve an application in its current form, with the reasons. It is a decision on the evidence submitted, not a permanent verdict — a company can address the issues and resubmit.

An FDA designation allowing closer, earlier engagement with the agency during development of a treatment for a serious unmet need.

The official document defining what a drug is approved to treat, in whom, at what dose, and with what warnings. If a use is not on the label, it has not been approved for that use.

The formal submission asking the FDA to approve a drug, containing the full evidence package.

Prescribing an approved drug for something outside its label. It is legal and sometimes appropriate, and it means the evidence for that specific use has not been through approval.

A status granted to treatments for rare diseases that brings incentives such as fees waived and a period of market exclusivity. It is an incentive to develop the drug, not a statement that it works.

A shortened FDA review timeline for treatments that would address a serious condition where options are limited. It changes how fast the review happens, not how likely approval is.